We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Richard
Lee
richard.lee@rmh.nhs.uk
Dr
Richard
Lee
richard.lee@rmh.nhs.uk
Sunnia
Gupta
sunnia.gupta@rmh.nhs.uk
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Rapid Diagnostic Centres (RDCs) are cancer diagnosis pathways where patients with non-specific but concerning symptoms of cancer (NSCS) can access rapid multidisciplinary assessment and/or investigations. This is part of the efforts of the NHS to improve early cancer diagnosis in the UK, which has historically been poor compared to countries of similar socio-economic status with comparable healthcare systems.
Those who present initially with NSCS are an important group to focus on as they are typically diagnosed with cancer at a later stage, potentially representing missed opportunities for diagnosis, and have worse outcomes.
The primary aim of this study is to assess the predictive value of biomarkers for differentiating cancer or serious benign pathologies within an RDC setting using independent or combined analysis of:
• Blood and non-blood biomarkers
• Symptoms from paper or electronic survey
• Routinely collected risk factor, clinical and imaging data
• Baseline genetic risk for cancer
Eligible patients shall include those seen in RDCs over 18 years of age, who have not been previously treated for or have a current diagnosis of active cancer prior to being seen in the RDC.
For participants that have provided informed consent to be enrolled in the study they shall be administered a symptom questionnaire at initial contact with biomarker samples obtained where possible at the same time as routine clinical care (i.e. blood biomarkers are collected in additional blood sample bottles at time of routine blood tests arranged by the clinical team).
By furthering the clinical validation of novel biomarkers this will help support each of the following objectives of RDCs in the future:
• Support earlier and faster cancer diagnosis
• Increase capacity through more efficient diagnostic pathways
• Deliver a better, personalised diagnostic experience
• Reduce unwarranted variation in referral for, access to and in the reliability of relevant diagnostic tests
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Exclusion criteria: • Previously treated (within 5 years preceding baseline scan) or current confirmed diagnosis of active malignancy prior to entry to ‘RDC pathway’ as their presentation to an RDC may be reflective of recurrent and/or synchronous cancer and therefore the predictive value of any investigation may not mirror that of patients with a new diagnosis of cancer. • Unable or unwilling to give informed consent.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Richard
Lee
richard.lee@rmh.nhs.uk
Dr
Richard
Lee
richard.lee@rmh.nhs.uk
Sunnia
Gupta
sunnia.gupta@rmh.nhs.uk
The study is sponsored by THE ROYAL MARSDEN NHS FOUNDATION TRUST and funded by NHS ENGLAND .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53826
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
